Logo image of ADAG

ADAGENE INC-ADR (ADAG) Stock Fundamental Analysis

NASDAQ:ADAG - Nasdaq - US0053291078 - ADR - Currency: USD

1.93  +0.18 (+10.29%)

Premarket: 1.93 0 (0%)

Fundamental Rating

2

ADAG gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. ADAG may be in some trouble as it scores bad on both profitability and health. ADAG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ADAG had negative earnings in the past year.
In the past year ADAG has reported a negative cash flow from operations.
ADAG had negative earnings in each of the past 5 years.
ADAG had a negative operating cash flow in each of the past 5 years.
ADAG Yearly Net Income VS EBIT VS OCF VS FCFADAG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ADAG has a Return On Assets (-37.44%) which is comparable to the rest of the industry.
ADAG has a Return On Equity (-66.16%) which is in line with its industry peers.
Industry RankSector Rank
ROA -37.44%
ROE -66.16%
ROIC N/A
ROA(3y)-35.43%
ROA(5y)-39.1%
ROE(3y)-63.08%
ROE(5y)-60.3%
ROIC(3y)N/A
ROIC(5y)N/A
ADAG Yearly ROA, ROE, ROICADAG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADAG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADAG Yearly Profit, Operating, Gross MarginsADAG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

3

2. Health

2.1 Basic Checks

ADAG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADAG has been increased compared to 1 year ago.
ADAG has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ADAG has a worse debt to assets ratio.
ADAG Yearly Shares OutstandingADAG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ADAG Yearly Total Debt VS Total AssetsADAG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -4.13, we must say that ADAG is in the distress zone and has some risk of bankruptcy.
ADAG has a Altman-Z score of -4.13. This is comparable to the rest of the industry: ADAG outperforms 43.70% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that ADAG is not too dependend on debt financing.
ADAG has a worse Debt to Equity ratio (0.10) than 65.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -4.13
ROIC/WACCN/A
WACC8.06%
ADAG Yearly LT Debt VS Equity VS FCFADAG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 2.30 indicates that ADAG has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.30, ADAG is doing worse than 72.12% of the companies in the same industry.
ADAG has a Quick Ratio of 2.30. This indicates that ADAG is financially healthy and has no problem in meeting its short term obligations.
ADAG's Quick ratio of 2.30 is on the low side compared to the rest of the industry. ADAG is outperformed by 70.14% of its industry peers.
Industry RankSector Rank
Current Ratio 2.3
Quick Ratio 2.3
ADAG Yearly Current Assets VS Current LiabilitesADAG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ADAG have decreased strongly by -71.88% in the last year.
Looking at the last year, ADAG shows a very negative growth in Revenue. The Revenue has decreased by -99.43% in the last year.
The Revenue for ADAG have been decreasing by -26.47% on average. This is quite bad
EPS 1Y (TTM)-71.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.81%
Revenue 1Y (TTM)-99.43%
Revenue growth 3Y-78.36%
Revenue growth 5Y-26.47%
Sales Q2Q%-87.35%

3.2 Future

ADAG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.90% yearly.
Based on estimates for the next years, ADAG will show a very strong growth in Revenue. The Revenue will grow by 33.04% on average per year.
EPS Next Y-5.45%
EPS Next 2Y-10.31%
EPS Next 3Y-22.38%
EPS Next 5Y4.9%
Revenue Next Year-27.93%
Revenue Next 2Y6.54%
Revenue Next 3Y-21.09%
Revenue Next 5Y33.04%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADAG Yearly Revenue VS EstimatesADAG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 2031 2032 100M 200M 300M
ADAG Yearly EPS VS EstimatesADAG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADAG. In the last year negative earnings were reported.
Also next year ADAG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADAG Price Earnings VS Forward Price EarningsADAG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADAG Per share dataADAG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A cheap valuation may be justified as ADAG's earnings are expected to decrease with -22.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.31%
EPS Next 3Y-22.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADAG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAGENE INC-ADR

NASDAQ:ADAG (7/21/2025, 8:00:00 PM)

Premarket: 1.93 0 (0%)

1.93

+0.18 (+10.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-24 2025-03-24/amc
Earnings (Next)07-23 2025-07-23
Inst Owners26.77%
Inst Owner Change0%
Ins Owners2.77%
Ins Owner ChangeN/A
Market Cap90.92M
Analysts77.78
Price Target5.87 (204.15%)
Short Float %0.23%
Short Ratio1.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-43.09%
PT rev (3m)-43.09%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 881.02
P/FCF N/A
P/OCF N/A
P/B 1.8
P/tB 1.8
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0
BVpS1.07
TBVpS1.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.44%
ROE -66.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.43%
ROA(5y)-39.1%
ROE(3y)-63.08%
ROE(5y)-60.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.65%
Cap/Sales 32.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.3
Quick Ratio 2.3
Altman-Z -4.13
F-Score2
WACC8.06%
ROIC/WACCN/A
Cap/Depr(3y)24.44%
Cap/Depr(5y)80.95%
Cap/Sales(3y)13.48%
Cap/Sales(5y)39.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.81%
EPS Next Y-5.45%
EPS Next 2Y-10.31%
EPS Next 3Y-22.38%
EPS Next 5Y4.9%
Revenue 1Y (TTM)-99.43%
Revenue growth 3Y-78.36%
Revenue growth 5Y-26.47%
Sales Q2Q%-87.35%
Revenue Next Year-27.93%
Revenue Next 2Y6.54%
Revenue Next 3Y-21.09%
Revenue Next 5Y33.04%
EBIT growth 1Y-51.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.18%
EBIT Next 3Y-23.23%
EBIT Next 5YN/A
FCF growth 1Y-4.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.38%
OCF growth 3YN/A
OCF growth 5YN/A